NL-OMON47747已完成不适用
Validation of the Dutch version of the Hip Outcome Score - Dutch Validation HOS
Reinier de Graaf Groep0 个研究点目标入组 136 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 136
研究概览
简要总结
Trial ended prematurely
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Patients who:
- •- are 18-65 years of age
- •- have physical examination and radiological examination suspect for FAI
- •- Inclusion will not interfere with standard care for FAI
- •- provided informed consent
- •- understand the Dutch language
排除标准
- •Patients who:
- •- have had prior surgery to the hip for FAI
- •- have pathological fracture or other metastatic pathology
- •- refuse to particpatie
- •- do not speak the Dutch language
研究者
相似试验
已完成
2 期
A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta ThalassemiaBeta Thalassemiainherited blood disorder10038158NL-OMON54921IMARA, Inc.15
已完成
不适用
*Dutch Marines study on Rabies antibody response after Boostering an intradermal pre-exposure scheme (MaRaBoo study)*Rabies10047438NL-OMON45312Academisch Medisch Centrum24
已完成
2 期
A Phase 2b/3 study to evaluate the safety, tolerability, and effects of livoletide (AZP-531), an unacylated ghrelin analog, on food-related behaviors in patients with Prader-Willi syndromePWSNL-OMON48225Millendo Therapeutics SAS23
已完成
不适用
A Phase 1 First-in-human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects With Myeloid Malignanciesbeenmergstoornis: MDS (myelodysplastisch syndroom/myelodysplasie)cancer of the blood10024324Acute myeloid leukemiamyelodysplastic SyndromeNL-OMON55859Amgen10
已完成
不适用
A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 plus Tilsotolimod and Other Therapy Combinations in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaNL-OMON49382AbbVie B.V.2